A vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | A | VTRS |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 33.83 billion USD | 12.42 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | November 18, 1999 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of A and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | A | VTRS |
|---|---|---|
| 5-Day Price Return | -0.15% | -0.37% |
| 13-Week Price Return | 5.57% | 21.58% |
| 26-Week Price Return | -13.01% | -1.39% |
| 52-Week Price Return | -14.23% | -9.97% |
| Month-to-Date Return | 4.62% | 21.85% |
| Year-to-Date Return | -10.59% | -14.46% |
| 10-Day Avg. Volume | 1.08M | 11.82M |
| 3-Month Avg. Volume | 1.89M | 12.30M |
| 3-Month Volatility | 27.93% | 32.62% |
| Beta | 1.27 | 0.89 |
Profitability
Return on Equity (TTM)
A
19.46%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
A
17.59%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 17.59% places A in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
A
21.36%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 21.36% places A in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Return on Equity (TTM) | 19.46% | -19.92% |
| Return on Assets (TTM) | 9.94% | -8.50% |
| Net Profit Margin (TTM) | 17.59% | -24.57% |
| Operating Profit Margin (TTM) | 21.36% | -26.54% |
| Gross Profit Margin (TTM) | 53.77% | 40.15% |
Financial Strength
Current Ratio (MRQ)
A
2.09
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
A’s Current Ratio of 2.09 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
A
0.57
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
A’s Debt-to-Equity Ratio of 0.57 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
A
254.50
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
With an Interest Coverage Ratio of 254.50, A demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 1.37 |
| Quick Ratio (MRQ) | 1.60 | 0.65 |
| Debt-to-Equity Ratio (MRQ) | 0.57 | 0.82 |
| Interest Coverage Ratio (TTM) | 254.50 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
A
0.82%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.82%, A offers a more attractive income stream than most of its peers in the Life Sciences Tools & Services industry, signaling a strong commitment to shareholder returns.
VTRS
4.58%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
A
23.76%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.82% | 4.58% |
| Dividend Payout Ratio (TTM) | 23.76% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
A
29.14
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
A’s P/E Ratio of 29.14 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
VTRS
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
A
5.13
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
A’s P/S Ratio of 5.13 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VTRS
0.88
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
A
5.00
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
A’s P/B Ratio of 5.00 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.14 | -- |
| Price-to-Sales Ratio (TTM) | 5.13 | 0.88 |
| Price-to-Book Ratio (MRQ) | 5.00 | 0.67 |
| Price-to-Free Cash Flow Ratio (TTM) | 28.58 | 7.29 |